Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension - Cwikla, J. B.; Wolin, E. M.; Pavel, Marianne Ellen; Phan, A. T.; Raderer, M.; Sedlackova, E.; Cadiot, G.; Capdevila, J.; Rindi, G.; Lombard-Bohas, C.; Liyanage, N.; Thanh, X-M. Truong; et al. (2017)
EVALuna2:34126